格隆汇10月22日丨热景生物(688068.SH)公布，公司收到参股公司舜景医药关于自主研制的创新药 SGC001 注射液 Ib 期临床研究获得了积极的初步结果的汇报。 舜景医药开展的创新药 SGC001 注射液分别在健康志愿者中和在前壁ST段抬高型心肌梗死患者中开展 了 2 个 I 期研究。截至本公告披露日，SGC001 注射液已完成 Ib 期临床试验并取得《一项评估 SGC001 在中国前壁ST 段抬高型心肌梗死且计划接受经皮冠状动脉介入治疗的患者中的安全性、耐受性、药代 动力学特征、免疫原性和初步疗效的随机、双盲、安慰剂对照、单次给药剂量递增的Ib期临床研究统计 分析表格》。 SGC001 是一款由舜景医药孙志伟教授研发团队联合首都医科大学北京市心肺血管疾病研究所杜杰教 授、李玉琳教授团队共同开发研制的急救用单克隆抗体药物，适用于急性心肌梗死（Acute Myocardial Infarction, AMI）(首先开展的适应症为"前壁 ST 段抬高型心肌梗死")患者的急救治疗。此前，针对AMI 疾病，暂无相关抗体药物进入临床研究阶段及审批上市。截至本公告日，SGC001 临床试验申请 （IND）已先后获 ...

智通财经APP讯，热景生物(688068.SH)发布公告，近日，公司收到参股公司北京舜景生物医药技术有 限公司(简称"舜景医药")关于自主研制的创新药SGC001注射液Ib期临床研究获得了积极的初步结果的汇 报。 初步有效性结果显示：在中国前壁ST段抬高型心肌梗死且接受经皮冠状动脉介入(PCI)治疗的患者中， SGC001在600mg和900mg剂量组较安慰剂组在心肌保护方面均有有效趋势，表现为心肌梗死面积百分比 (IS%)减少，高敏肌钙蛋白I(hsTnI)和高敏C反应蛋白(hs-CRP)回复至正常水平所需时间更短;与安慰剂组 相比，有随着剂量增加疗效增加的趋势，中高剂量组心肌梗死面积百分比中位数分别降低20.5%和 38.1%。该项目后续将继续按照临床试验方案开展临床工作。 ...

初步有效性结果显示：在中国前壁ST段抬高型心肌梗死且接受经皮冠状动脉介入(PCI)治疗的患者中， SGC001在600mg和900mg剂量组较安慰剂组在心肌保护方面均有有效趋势，表现为心肌梗死面积百分比 (IS%)减少，高敏肌钙蛋白I(hsTnI)和高敏C反应蛋白(hs-CRP)回复至正常水平所需时间更短;与安慰剂组 相比，有随着剂量增加疗效增加的趋势，中高剂量组心肌梗死面积百分比中位数分别降低20.5%和 38.1%。该项目后续将继续按照临床试验方案开展临床工作。 智通财经APP讯，热景生物(688068.SH)发布公告，近日，公司收到参股公司北京舜景生物医药技术有 限公司(简称"舜景医药")关于自主研制的创新药SGC001注射液Ib期临床研究获得了积极的初步结果的汇 报。 ...

热景生物公告，近日收到参股公司北京舜景生物医药技术有限公司关于自主研制的创新药SGC001注射 液Ib期临床研究获得了积极的初步结果的汇报。具体数据显示，在前壁ST段抬高型心肌梗死患者中， SGC001在600 mg和900 mg剂量组较安慰剂组在心肌保护方面均有有效趋势，心肌梗死面积百分比中位 数分别降低20.5%和38.1%。SGC001注射液在前壁ST段抬高型心肌梗死患者人群中安全耐受性良好，未 发生3级及3级以上不良事件和严重不良事件。 ...

Group 1: Fund Performance and Holdings - The performance of the "Yongying Technology Smart Selection" fund has been outstanding, with a net asset value increase of 194.49% in the first three quarters, making it a leader among all funds [4][10] - The fund's scale surged from 1.166 billion to 11.521 billion, a nearly tenfold increase in a single quarter [7] - The top three holdings of the fund are "Xinyi Sheng," "Zhongji Xuchuang," and "Tianfu Communication," each with a market value exceeding 1 billion [4][5] Group 2: Investment Focus - The fund primarily focuses on the global cloud computing industry, with significant investments in optical communication (CPO) and PCB sectors [4][8] - The fund maintains a high stock position, with over 91% of its portfolio in equities [4][10] - The investment strategy emphasizes high-concentration holdings in key sectors, reflecting a clear investment style [4] Group 3: Market Trends and Insights - The global cloud computing industry remains a key area of focus, with AI model values increasing and significant investments expected in AI computing power [8] - The anticipated technological advancements in optical communication and PCB industries are expected to create new opportunities by 2027 [8] - The "Changcheng Pharmaceutical Industry Selected" fund has also shown strong performance, with a 102.02% increase in the first three quarters, indicating a robust interest in the innovative drug sector [10][13] Group 4: Changes in Holdings - The "Changcheng Pharmaceutical Industry Selected" fund has increased its stock position to over 82%, with significant investments in companies like "Xinda Biopharmaceutical" and "Sanjing Pharmaceutical" [10][12] - The fund has also seen a nearly 60% increase in scale, from 1.132 billion to 1.790 billion [13] - The focus on innovative drugs is shifting towards individual stock selection, emphasizing the global competitiveness and scarcity of core pipelines [13]

Group 1 - The core viewpoint of the news highlights a significant rise in innovative drug concept stocks, indicating positive market sentiment in this sector [1] Group 2 - Kintor Pharmaceutical saw an increase of over 10% in its stock price [1] - AngliTech experienced a rise of over 8% [1] - Other companies such as Hotgen Biotech, Asia-Pacific Pharmaceutical, and Shuyou Shen also showed upward movement in their stock prices [1]

Core Viewpoint - The stock of Hotgen Biotech has shown significant volatility, with a year-to-date increase of 193.53%, but recent performance indicates mixed trends in the short term [1][2]. Company Overview - Hotgen Biotech, established on June 23, 2005, and listed on September 30, 2019, specializes in the research, production, and sales of in vitro diagnostic reagents and instruments [1]. - The company's revenue composition includes 70.87% from testing reagents, 19.79% from testing instruments, 8.17% from other sources, and 1.17% from biological raw materials [1]. Financial Performance - For the first half of 2025, Hotgen Biotech reported a revenue of 204 million yuan, a year-on-year decrease of 18.04%, and a net profit attributable to shareholders of -83.99 million yuan, down 93.24% year-on-year [2]. - The company has distributed a total of 440 million yuan in dividends since its A-share listing, with 17.34 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 4.14% to 6,938, while the average circulating shares per person decreased by 3.74% to 13,362 shares [2]. - Notable institutional shareholders include Huatai-PineBridge Innovation Medicine Mixed A and ICBC Frontier Medical Stock A, with some new entries and changes in holdings among the top ten circulating shareholders [3]. Market Activity - On October 21, the stock price rose by 2.08% to 181.52 yuan per share, with a trading volume of 48.64 million yuan and a turnover rate of 0.29% [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent net buy of 47.83 million yuan on July 4 [1].

10月17日，热景生物涨5.26%，截至发稿，报186.64元/股，成交1.06亿元，换手率0.62%，总市值173.03 亿元。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 资料显示，北京热景生物技术股份有限公司位于北京市大兴区中关村科技园区大兴生物医药产业基地庆 丰西路55号院7号楼1-5层，成立日期2005年6月23日，上市日期2019年9月30日，公司主营业务涉及研 发、生产和销售体外诊断试剂及仪器。主营业务收入构成为：检测试剂70.87%，检测仪器19.79%，其 他8.17%，生物原料1.17%。 责任编辑：小浪快报 从基金十大重仓股角度 数据显示，国投瑞银基金旗下1只基金重仓热景生物。国投瑞银上证科创板200指数发起式A（023518） 二季度持有股数1.34万股，占基金净值比例为1.12%，位居第三大重仓股。根据测算，今日浮盈赚取约 12.53万元。 截至发稿，赵建累计任职时间12年25天，现任基金资产总规模38.48亿元，任职期间最佳基金回报 172 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300642 | 透景生命 | 25.85 | 10.38% | 29.49万 | | 7.56亿 | | 603222 | 济民健康 | 10.97 | 10.03% | 35.34万 | | 3.74亿 | | 688273 | 麦澜德 | 43.90 | 9.75% | 4.75万 | | 2.01亿 | | 301087 | 可孚医疗 | 43.10 | 7.86% | 7.27万 | | 3.07亿 | | 688068 | 热景生物 | 170.79 | 6.96% | 3.47万 | | 5.91亿 | | 688108 | 赛诺医疗 | 30.26 | 5.22% | 44.79万 | | 13.24亿 | | 300238 | 冠昊生物 | 15.61 | 4.48% | 8.54万 | | 1.32亿 | | 300003 | 乐普医疗 | 17.83 | 3.72% | 37.96万 | | 6.72亿 | | ...

Core Viewpoint - The company is optimizing its equity structure and enhancing long-term incentive mechanisms to attract and retain talent, thereby promoting stable long-term business development through a capital increase and equity incentive plan for its subsidiary, Yaojing Gene [1] Group 1: Capital Increase and Equity Incentive - The company plans to increase capital in Yaojing Gene through a newly established limited partnership (employee stock ownership platform) with a total investment amount of 16 million yuan at a price of 1.6 yuan per registered capital [1] - The company will waive its preferential subscription rights for this capital increase, which constitutes a related party transaction but does not qualify as a major asset restructuring under the relevant regulations [1] Group 2: Management Involvement - The company's controlling shareholder, actual controller, chairman, and general manager, Lin Changqing, will serve as the chairman of Yaojing Gene, while the board secretary and deputy general manager, Shi Yongzhan, will act as the financial officer of Yaojing Gene [1] - Lin Changqing will also be the general partner of the employee stock ownership platform being established by Yaojing Gene [1]